Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) is a neuroscience-focused biopharmaceutical company that entered public markets through a de-SPAC business combination with ARYA Sciences Acquisition Corp II, a blank-check vehicle sponsored by Perceptive Advisors that completed its initial public offering in 2020. Originally carved out of Pfizer's neuroscience research portfolio and backed by Bain Capital, Cerevel is focused on developing therapies for brain diseases including Parkinson's disease, epilepsy, and schizophrenia. The Form 8-K filed July 30, 2020 represents a key regulatory milestone in the company's transaction and listing process within the healthcare and life sciences sector. For full filing history, sponsor details, and comparable SPAC transactions, sign up for complete data access on SpacDesk.